Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.55 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.55 |
| ▸ | TNFSF11 | O14788 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CFD | P00746 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.39 |
| ▸ | GGT1 | P19440 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29140951 | 0.98 | CYP4F2 (0.53) | CYP4F2CYP4A11TNFSF11KDM4EALDH1A1 | |
| SCHEMBL24445868 | 0.85 | CYP4F2 (0.50) | CYP4F2CYP4A11TNFSF11KDM4EALDH1A1 | |
| SCHEMBL24436700 | 0.85 | CYP4F2 (0.50) | CYP4F2CYP4A11TNFSF11KDM4EALDH1A1 | |
| SCHEMBL28133983 | 0.84 | CYP4F2 (0.49) | CYP4F2CYP4A11TNFSF11KDM4EALDH1A1 | |
| SCHEMBL12768204 | 0.83 | ACHE (0.49) | CYP4F2CYP4A11TNFSF11KDM4EALDH1A1 | |
| SCHEMBL24436814 | 0.83 | CYP4F2 (0.47) | CYP4F2CYP4A11TNFSF11KDM4EALDH1A1 | |
| SCHEMBL28782428 | 0.81 | KDM4E (0.46) | CYP4F2CYP4A11TNFSF11KDM4EALDH1A1 | |
| SCHEMBL12768196 | 0.81 | CYP4F2 (0.46) | CYP4F2CYP4A11TNFSF11KDM4EALDH1A1 | |
| SCHEMBL13074358 | 0.79 | CYP4F2 (0.45) | CYP4F2CYP4A11TNFSF11KDM4EALDH1A1 | |
| SCHEMBL12727395 | 0.79 | CFD (0.58) | CYP4F2CYP4A11TNFSF11KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111393282-A | Preparation method of 2,4, 5-trifluorophenylacetic acid | 湖南复瑞生物医药技术有限责任公司 | 2020-07-10 | — | — | CN | claimed |
| US-10483466-B2 | P-doping cross-linking of organic hole transporters | SIEMENS AKTIENGESELLSCHAFT (DE) | 2019-11-19 | — | — | US | claimed |
| EP-3114715-B1 | P-DOPING CROSS-LINKING OF ORGANIC HOLE TRANSPORTERS | SIEMENS AG (DE) | 2019-10-30 | — | — | EP | claimed |
| US-20180198069-A1 | P-Doping Cross-Linking Of Organic Hole Transporters | SIEMENS AKTIENGESELLSCHAFT (DE) | 2018-07-12 | — | — | US | claimed |
| CN-105949072-A | Preparation method and intermediate of beta-substituted amino-gamma-substituted aryl butyric acid | 苏州敬业医药化工有限公司 | 2016-09-21 | — | — | CN | claimed |
| EP-2331545-A2 | IMPROVED PROCESS FOR PREPARATION OF (2R)-4-OXO-4-[3- (TRIFLUOROMETHYL)-5,6-DIHYDRO [1,2,4]-TRIAZOLO[4,3-A]PYRAZIN- 7(8H)-YL]-L-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE&NEW IMPURITIES IN PREPARATION THEREOF | Cadila Healthcare Limited (IN) | 2011-06-15 | — | — | EP | claimed |
| WO-2010032264-A2 | IMPROVED PROCESS FOR PREPARATION OF (2R)-4-OXO-4-[3- (TRIFLUOROMETHYL)-5,6-DIHYDRO [1,2,4]-TRIAZOLO[4,3-A]PYRAZIN- 7(8H)-YL]-L-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE & NEW IMPURITIES IN PREPARATION THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2010-03-25 | — | — | WO | claimed |
| US-12509421-B2 | Preparation and application of deuterated 4-phenyl-4-piperidinols | NANCHANG DOUBLE ANGEL BIOTECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2025-12-30 | — | — | US | disclosed |
| US-20250304534-A1 | Preparation and Application of Deuterated 4-Phenyl-4-Piperidinols | NANCHANG DOUBLE ANGEL BIOTECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| CN-120154006-A | Application of p-fluorobenzaldehyde and composition containing p-fluorobenzaldehyde in attracting cotton bollworms | 中国农业科学院植物保护研究所 | 2025-06-17 | — | — | CN | disclosed |
| CN-117384029-B | Synthesis method of 2,4, 5-trifluoro phenylacetic acid | 山东国邦药业有限公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-117384029-A | Synthesis method of 2,4, 5-trifluoro phenylacetic acid | 山东国邦药业有限公司 | 2024-01-12 | — | — | CN | disclosed |
| CN-116478169-A | Synthesis method of sitagliptin | 黑龙江岭润生物科技有限公司 | 2023-07-25 | — | — | CN | disclosed |
| EP-1798250-A2 | Molecules suitable for binding to a metal layer for covalently immobilizing biomolecules | INTERUNIVERSITAIR MICROELEKTRONICA CENTRUM vzw (IMEC) (BE) | 2007-06-20 | — | — | EP | disclosed |
| CN-1845674-A | Novel crystalline forms of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor | MERCK & CO INC (US) | 2006-10-11 | — | — | CN | disclosed |
| CN-1761642-A | Process for the preparation of chiral beta-amino acid derivatives by asymmetric hydrogenation | MERCK & CO INC (US) | 2006-04-19 | — | — | CN | disclosed |
| US-20040068141-A1 | Process for the synthesis of trifluorophenylacetic acids | ARMSTRONG JOSEPH D (US) | 2004-04-08 | — | — | US | disclosed |
| EP-1077701-A4 | ANTI-VIRAL COMPOUNDS | LILLY CO ELI (US) | 2002-03-20 | — | — | EP | disclosed |
| EP-1077701-A1 | ANTI-VIRAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999059587-A1 | ANTI-VIRAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040068141-A1 | Process for the synthesis of trifluorophenylacetic acids | PCCA, PAH, PFAS | CYP4F2 17/4885CYP4A11 302/4885TNFSF11 4849/4885 |
| US-20250304534-A1 | Preparation and Application of Deuterated 4-Phenyl-4-Piperidinols | DHPS, OPRL1, QDPR | CYP4F2 562/4885CYP4A11 159/4885TNFSF11 4852/4885 |
| US-12509421-B2 | Preparation and application of deuterated 4-phenyl-4-piperidinols | OPRD1, OPRK1, OPRL1 | CYP4F2 858/4885CYP4A11 229/4885TNFSF11 4748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.